Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the pricing of an underwritten public offering of 4,150,000 shares of common stock at an offering price of $7.25 per share.  The shares will begin trading on The NASDAQ Capital Market on October 25, 2013 under the symbol "SRNE." The gross proceeds to Sorrento from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about October 30, 2013, subject to customary closing conditions. Sorrento has granted the underwriters a 45-day option to purchase up to an additional 622,500 shares of common stock to cover over-allotments, if any.

Sorrento intends to use the net proceeds received from the offering to fund its research and development activities, including its registrational clinical trial of Cynviloq™, for working capital, other general corporate purposes, and possibly acquisitions of other companies, products or technologies.

In connection with its listing on The NASDAQ Capital Market, Sorrento's common stock will cease trading on the OTC QB.   

Aegis Capital Corp. is acting as the sole book-running manager for this offering.

CRT Capital is acting as co-manager for this offering. 

A shelf registration statement and accompanying base prospectus on Form S-3 relating to the shares was filed with the Securities and Exchange Commission and is effective.  A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov. Copies of the final prospectus supplement, when available, may be obtained from the SEC's web site or the offices of Aegis C
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ill. , Jan. 15, 2014 The Cadence ... Medical Fitness Center by the Medical Fitness Association, a ... to achieve their full potential. The Cadence Fitness & ... the western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Ariz. , July 28 Matrixx Initiatives, Inc. (Nasdaq: MTXX ... 2011 first quarter ended June 30, 2010 , will be released after ... call will be held the following morning on Wednesday, August 4, 2010 ... , , ...
... Eli Lilly and Company (NYSE: LLY ) today announced that the ... by the U.S. District Court for the Eastern District of Michigan ... , , ... Gemzar,s method-of-use patent. We continue to believe that our Gemzar method-of-use patent should ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 First Quarter Financial Results 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 3
(Date:4/14/2014)... SAN FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a ... destruction of human red blood cells exposed to plasma ... anemia (AIHA). The article entitled "TNT003, an inhibitor of ... cold agglutinin disease patient autoantibodies" was published on-line in ...
(Date:4/14/2014)... still more evidence that antibiotics can contribute to obesity. ... Antimicrobial Agents and Chemotherapy suggests that patients ... changes in their gut microbiota. , The study, ... followed 48 patients who were being treated long-term with ...
(Date:4/14/2014)... , , Scientists from UNC,s Frank Porter Graham Child Development ... the state,s program to prepare four-year-olds for success in ... Pre-K show significant gains across all areas of learning. ... rate during their participation in NC Pre-K than expected ...
(Date:4/14/2014)... more than a decade Chang Lu, associate professor of chemical ... development of tools to efficiently analyze living cells. The long-term ... of diseases. , In his lab , Lu and ... molecular events inside cells. These devices promote high sensitivity and ...
(Date:4/14/2014)... , COLUMBUS, Ohio Heart patients with beliefs about health ... skip sessions of cardiac rehabilitation, new research suggests. , In ... beliefs referred to as "irrational health beliefs" on a ... adherence to a prescribed cardiac rehab program. , Among ...
Breaking Medicine News(10 mins):Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Long-term antibiotic treatment for Q fever causes weight gain 2Health News:Study gives high marks to NC Pre-K program 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 2Health News:Irrational health beliefs linked to skipping cardiac rehab sessions 3
... Imaging Ltd.,(the "Company") (Nasdaq: EMITF ), today announced ... the trustee for the holders of the,Series A, B ... the "Notes",respectively), that due to the signing of a ... Co., the controlling shareholder of,the Trustee, and Brightman, Almagor ...
... stopping infection , , TUESDAY, April 29 (HealthDay News) -- Most ... virus itself, but new research suggests that focusing on the ... because human cells mutate at much slower rates than does ... mutating around the drug, scientists explained. , The research is ...
... is available in German . , Leipzig. ... the Czech Republic and Poland did not so far lead ... Central Europe, there are other reasons for the presence of ... are the findings of a research project conducted by the ...
... Scientists at Johns Hopkins have outlined a new path ... and asthma based on a new understanding of the ... cavities. , Researchers say their findings, to be ... Allergy and Clinical Immunology, are the first evidence describing ...
... 29 Baptist Health System, one,of Alabama,s largest ... Group to bring together the health-improvement,needs of local ... at its four hospitals. Aegis brings nearly 20 ... services with the unique,healthcare needs of area employees., ...
... Success, NEW YORK, April 29 Flashpoint ... of the Omnicom Group,(NYSE: OMC ), was ... Medical,Advertising News at the publication,s annual Manny Awards ... by innovative thinking, powerful creative, and a,collaborative approach ...
Cached Medicine News:Health News:Elbit Imaging Ltd. Announces Termination of Service of Trustee for Holders of Series A, B and C Notes 2Health News:Elbit Imaging Ltd. Announces Termination of Service of Trustee for Holders of Series A, B and C Notes 3Health News:Researchers Tackle HIV From a New Angle 2Health News:Researchers Tackle HIV From a New Angle 3Health News:Shrinkage and aging are Europe-wide challenges 2Health News:Shrinkage and aging are Europe-wide challenges 3Health News:Shrinkage and aging are Europe-wide challenges 4Health News:Immune system kick-started in moist nasal lining in sinusitis, asthma and colds 2Health News:Immune system kick-started in moist nasal lining in sinusitis, asthma and colds 3Health News:Alabama's Baptist Health System and Aegis Health Group Partner to Address Local Employers Health-Management Concerns 2Health News:Flashpoint Medica Named Agency of Year by Medical Advertising News 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: